combisyn stungulyf, dreifa 14,0/3,5 % w/v
norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - stungulyf, dreifa - 14,0/3,5 % w/v
combisyn tafla 250 mg
norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 250 mg
combisyn tafla 50 mg
norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 50 mg
flunixin (flunixin solutions for injection) stungulyf, lausn 50 mg/ml
norbrook laboratories (ireland) limited - flunixinum meglúmínsalt - stungulyf, lausn - 50 mg/ml
noromectin (noromectin pour-on) áhella, lausn 0,5 % w/v
norbrook laboratories (ireland) limited - ivermectinum inn - Áhella, lausn - 0,5 % w/v
noromectin (noromectin 1.87% oral paste for horses) pasta til inntöku 1,87 %
norbrook laboratories (ireland) limited - ivermectinum inn - pasta til inntöku - 1,87 %
noromectin stungulyf, lausn 1 % w/v
norbrook laboratories (ireland) limited - ivermectinum inn - stungulyf, lausn - 1 % w/v
noromectin drench (noromectin drench 0.8 mg/ml oral solution for sheep) mixtúra, lausn 0,8 mg/ml
norbrook laboratories (ireland) limited - ivermectinum inn - mixtúra, lausn - 0,8 mg/ml
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystic fibrosis - Önnur öndunarfæri - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
sugammadex mylan
mylan ireland limited - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.